Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Neoplasms 4 Esophageal Squamous Cell Carcinoma 3 Uterine Cervical Neoplasms 2 Lymphatic Metastasis 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Ductal, Breast 1

Interventions

Carboplatin 66 Cisplatin 57 Paclitaxel 42 Radiotherapy 35 Pemetrexed 34 Gemcitabine 31 Docetaxel 31 Etoposide 24 pembrolizumab 21 Vinorelbine 20 Erlotinib Hydrochloride 13 Magnetic Resonance Spectroscopy 12 Gefitinib 11 Specimen Handling 10 Radiosurgery 10 Drug Therapy 10 Bevacizumab 10 durvalumab 9 Nivolumab 9 Vinblastine 6 Topotecan 6 Surgical Procedures, Operative 6 Cyclophosphamide 6 Standard of Care 5 Platinum 5 Immunoglobulin G 5 Ifosfamide 5 Disulfides 5 Dexamethasone 5 paclitaxel poliglumex 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lung Neoplasms × TP protocol × Clear all

NCT00801736 2013-12-10

ET

University College, London

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡